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Abstract: Continuous glucose monitoring (CGM) devices can measure blood glucose levels through 
interstitial measurements almost continuously (1-5min sampling period). However, they are not as accurate 
as glucose readings from blood measurements. The relation between tissue and blood glucose is dynamic 
and the sensor signal can degrade over time. In addition, CGM readings contains high frequency noise and 
can drift between measurements. However, maintaining continuous glucose monitoring has the potential to 
improve the level of glycemic control achieved and reduce nurse workload. For this purpose, a simple model 
was designed and tested to see the effect of inherent CGM error on the insulin therapy protocol, STAR 
(Stochastic TARgeted).   
 
An error model was generated from 9 patients that had one Guardian Real-Time CGM device (Medtronic 
Minimed, Northridge, CA, USA) inserted into their abdomen as part of an observation trial assesing the 
accuracy of CGM measurements compared to a blood gas analyser and glucometer readings. A resulting 
error model was then used to simulate the outcomes if the STAR protocol was guided by CGM values on 
183 virtual patients. CGM alarms for hyper- and hypo-glycaemic region were included to improve patient 
safety acting as ‘guardrails’. The STAR CGM protocol gave good performance and reduced workload by 
~50%, reducing the number of measurements per day per patient from 13 to 7. The number of hypoglycaemic 
events increased compared to the current STAR from 0.03% <2.2mmol/L to 0.32%. However, in comparison 
to other published protocols it is still a very low level of hypoglycaemia and less than clinically acceptable 
value of 5% <4.0mmol/L. More importantly this study shows great promise for the future of CGM and their 
use in clinic. With the a newer generation of sensors, specifically designed for the ICU,  promising less noise 




Continuous glucose monitoring (CGM) devices, with their 1-
5 minute measurement interval, have recently been used to 
monitor critical care  patients’  blood glucose (BG) in a more 
effective, less invasive manner than intermittent bedside BG 
measurements alone (Pretty et al., 2010, Signal et al., 2010, 
Beardsall et al., 2005, Harris et al., 2010, Holzinger et al., 
2010, Brunner et al., 2011). CGM devices typically consist of 
a small pager-like monitoring device that receives a signal 
from a sensor inserted into the subcutaneous layer, just beneath 
the skin. Calibration algorithms convert the signal into a 
meaningful glucose concentration by comparing it to known 
calibration BG measurements, which are entered into the 
monitor by the user every 6-12 hours. 
 
Typical glycaemic control protocols require BG measurements 
every 1-4 hours (Evans et al., 2012, Lonergan et al., 2006, 
Plank et al., 2006, Blaha et al., 2009), resulting in 
approximately 13 blood draws a day per patient. This 
represents a significant part of nurse workload(Carayon et al., 
2005, Holzinger et al., 2005). CGM devices have the potential 
to drastically reduce the number of BG measurements per day 
while ensuring patient safety and increased time in the desired 
BG target band.  
 
However, CGM devices can display suboptimal accuracy 
resulting from error or delay in calibration measurement, 
sensor drift and delayed glucose diffusion (Castle et al., 2010, 
Facchinetti et al., 2014). Thus, before CGM can become 
ubiquitous in the care of critically ill patients these errors and 
the effects of these errors on BG control must first be 
quantified and understood.    
 
This paper presents a simple CGM error model, including drift, 
created by comparing CGM readings and true BG values using 
data from 9 patients admitted to the Christchurch Intensive 
Care Unit (ICU). The impact of the CGM error is then 
evaluated in virtual trials using the STAR protocol (Stochastic 
TARgeted) (Evans et al., 2012), which is now standard care in 
Christchurch ICU.  Alarms and guardrail threshold settings 
were also investigated to insure patient safety especially in the 
hypoglycaemic region. These alarms are typically built in to 
CGM devices and would thus require no extra programming 
to use.  
  
     
 
 
2. PATIENTS & METHODS 
2.1 CGM Error Model  
 2.1.1 Patients 
This part of the study uses data from 9 patients admitted to the 
Christchurch Hospital ICU that were enrolled in an 
observational pilot study of CGM (Signal, 2013). Inclusion  
criteria  was  two consecutive  BG  measurements  greater  than  
8mmol/L,  indicating  the  need  for insulin therapy using the 
STAR protocol. Exclusion criteria were an anticipated ICU 
admission period of less than 3 days. All patients had one 
Guardian Real-Time CGM device (Medtronic Minimed, 
Northridge, CA, USA) inserted into their abdomen, providing 
real-time CGM values every 5 minutes. The patients all 
remained under insulin therapy treatment for > 24 hours. This 
study was approved by the Upper South Regional Ethics 
Committee, New Zealand. Table 1 summaries the patient 
demographics.  
Table 1. Summary of CGM study patient characteristics. Data 
are show as median [interquartile range] where appropriate. 
N 9 
Age (years) 57 [38-64] 
Gender (M/F) 5/4 
APACHE II score  22 [17 – 28] 
Hospital mortality (L/D) (5/4) 
Duration of CGM (days) 3.6 [2.5 – 5.7]  
 
 2.1.2 Model   
A simple CGM error model was created, separating the error 
in to two distinct parts of noise and drift defined:  
                   𝐶𝐺𝑀 =  𝐵𝐺𝑟𝑒𝑎𝑙 + 𝑛𝑜𝑖𝑠𝑒 + 𝑑𝑟𝑖𝑓𝑡              Eq.1 
Where drift was assumed to be a constant linear bias. It was 
defined as the rate of increase in discrepancy between the 
CGM trace and reference BG measurements over time 
between calibration BG measurements. Thus, drift was 
assumed to start at a calibration measurement and finish at the 
following calibration measurement.  
The magnitude of the accumulated drift between any two 
calibrations was found using a drift distribution created by 
comparing true BG values and CGM values for each paired 
data. The absolute values of the drift error was taken and the 
errors were normalised with regards to the time spent since last 
CGM calibration to obtain a drift per hour value. Figure 1 
shows the error distribution achieved for each patient and the 
entire cohort.  
The error distribution of the entire cohort was best described 
by an exponential distribution with a mu = 0.4764. It was 
assumed that positive and negative drifts are equitably 
distributed (50-50).  
 
Figure 1: Distribution for each individual patient (A) and the 
entire cohort (B) 
 
High frequency sensor noise was generated using Gaussian 
noise distribution from Golberg et al. (Goldberg et al., 2004). 
This distribution can been seen in Figure 2 where it is ¼ of the 
size of the original distribution published. This value was 
selected to match the data observed in the observational trials. 
The reduction represents the significant improvement in 
sensor noise since its publication. It is evident then from Figure 
3 that this combination of error models to create a CGM trace 
in simulation displays trends and measurement error to that of 
a real CGM trace. A range of type CGM traces were chosen to 
be displayed in Figure 3 to illustrate the robustness of the 
model.     
 



























































     
 
 
Figure 1: 1/4 Goldberg noise distribution used to model the 
high frequency noise seen in CGM signals 
 
2.2 Virtual Trials  
The effect of CGM error on insulin therapy was tested using a 
clinically validated virtual trial approach (Chase et al., 2010). 
This approach uses virtual patients, each comprising an insulin 
sensitivity (SI) profile identified from the clinical data of a real 
patient using a pharmacokinetic-pharmacodynamic (PK-PD) 
model of the glucose-insulin system (Lin et al., 2011). The SI 
profile can then be used with the PK-PD model to simulate the 
glycaemic outcome of different insulin and nutrition 
interventions. 
In this study the STAR protocol was tested. In addition, CGM 
measurements were simulated using Equation 1. The impact 
on performance and safety using CGM instead of the ~13 
measurements/day required by STAR (Fisk et al., 2012) was 
then assessed.     
 2.2.1 Patients  
Virtual trials were performed using retrospective data from 
183 patients treated by accurate glycaemic control protocols at 
Christchurch Hospital ICU between 2011 and 2013. All 
patients were treated with the tablet-based STAR protocol for 
> 24hrs. Cohort demographics are presented in Table 2.  
Table 2. Cohort demographics of the patients used for virtual 
trials. Data are presented as median [interquartile range] where 
appropriate. 
N 183 
Age (years) 65 [54-72] 
Gender (M/F) 123/60 
APACHE II score  21 [15 – 25]  
Hospital mortality (L/D) 131/52 
 
Figure 3: Comparing CGM traces simulated using the CGM 
error model and BG calibration measurements to the real CGM 
trace from observational trials.  
























































































     
 
 2.2.2 Alarm Design  
To ensure patient safety from hypoglycaemia (BG < 4.5 
mmol/L) or hyperglycaemia (BG > 9 mmol/L), CGM alarms 
were used in simulation. Every time CGM BG values reach the 
upper or lower threshold, a BG measurement was performed. 
If the BG value at the lower threshold (CGM BG < 4.5 
mmol/L) differed by more than 0.5mmol/L the CGM device 
was recalibrated, correcting the sensor drift. The same process 
was undertaken at the upper threshold (CGM BG > 9 mmol/L) 
if the measurements differed by more than 1.0mmol/L. The 
threshold values were selected to optimise performance, safety 
and workload. Otherwise CGM measurements were used as 
BG measurements in STAR to determine insulin and nutrition. 
These alarms values were optimised by repeated simulation 
with hypoglycaemic alarm values ranging from 3-5mmol/L 
and hyperglycaemic alarm values ranging from 8-10mmol/L 
both in steps of 0.5mmol/L. The alarm values selected 
provided the best trade off between performance, safety and 
workload.     
    
2.3 Analysis Methods  
Monte Carlo (MC) methods were employed to reduce the 
impact of randomly sampled outliers on results. A 50-run MC 
simulation was completed for each virtual patient. Blood 
glucose values were generated using the clinically validated 
Intensive Control Insulin-Nutrition-Glucose (ICING) model 
of the glucose-insulin system (Lin et al., 2011) was used. 
Sensor drift and noise was added to the measurements using 
the CGM model. These BG measurements were then given to 
the STAR protocol generate insulin and nutrition 
interventions. This situation simulates what it would be like if 
CGM devices were being used to guide the protocol in clinic.  
 Metrics such as %time in the desired 4.4 – 8mmol/L band, 
%time below 2.2mmol/L and number of blood draws per 
patient per day were used to assess the performance, safety and 
resulting workload of using CGM devices to guide the STAR 
protocol. Results were compared to a 50-run MC of the STAR 
protocol without CGM error and the clinical results of the 183 
patients.  
 
3. RESULTS & DISCUSSION 
 
3.1 Virtual Trials Results  
During virtual trials, the STAR protocol guided by CGM 
measurements achieved a median BG of 7.0 mmol/L with 
72.2% time in the desired 4.4-8.0 mmol/L target band. Table 3 
summarises the performance of the STAR CGM protocol and, 
for comparison, also shows clinical data and results from 
virtual trials of the same patients with the STAR protocol 
without the additional CGM error model. 
Table 3 illustrates the compromise in target-band performance 
that was necessary with the STAR CGM protocol to meet 
safety and workload requirements. Compared with clinical 
results and STAR, time in the 4.4-8.0 mmol/L band was 
reduced by approximately 15%. However, the average 
measurement interval increased by ~50%.  
Importantly, the STAR CGM protocol is still safe for patients 
even with the increased error in BG measurements. STAR 
CGM has less time in the hypoglycaemic region than many 
other published protocols (Finfer et al., 2012, Preiser et al., 
2008, Brunkhorst et al., 2008, Bagshaw et al., 2009, Treggiari 
et al., 2008) which require much hire number of blood draws 
per day. The time below 4.0mmol/L is below a clinically 
specified value of 5%. 
 
Table 3. Results of virtual trial simulations as well as clinical 
data. Data are presented as median [interquartile range] where 
appropriate. STAR MC contains no variation as error is not 
added to the measurements generated in simulation. Hence, 
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MC 
Clinical 












% time in 
4.4-8.0 
mmol/L 
81.0 72.2 [72-73] 81.3 
% time < 
4.4 
mmol/L 
1.59 4.7 [4.6-4.9] 1.69 









It is worth to noting that these results represent a worst case 
scenario as the STAR protocol was not modified to take into 
account the real-time BG readings available or the trend data. 
Thus, additional dextrose/insulin boluses when hypo/hyper 
alarms are triggered and proved accurate would most likely 
increase the performance and safety seen. However, this would 
increase the workload required and this initial investigation 
aimed to see how much the current workload could be reduced 
using the current standard of care.  
Also the real-time Guardian devices the error model was 
created from were not designed for clinical use. These CGM 
devices are designed to help Type I and II diabetic patients 
regulate their BG levels. Thus, there are many factors when 
using these devices in critical care that are known to impact 
the performance, such as patients diagnosed with sepsis, septic 
  
     
 
shock and peripheral oedema (Lorencio et al., 2012). 
Additionally certain medications/therapies commonly used in 
ICU, such as paracetamol, can influence CGM performance 
(Moser et al., 2010). Therefore, the newer generation of 
sensors that are emerging specifically designed for hospital 
use, such as the Medtronic Sentrino (Medtronic, 2012), are 
likely to be more accurate and be less affected by these factors 
all of which would improve performance.  
Drift reduces performance the most as it is an unseen bias. To 
investigate the effect of reduced drift half guardian noise was 
simulated with on the same cohort. This produced less draws 
per day, only 1.38% time <4.4mmol/L and 78% time in the 
desired 4.4-8mmol/L band. These results are much improved 
and show great promise for the future CGM devices being 
developed to aid in reducing nurse workload.   
 
4. CONCLUSIONS 
The study aimed to show the effects of using a CGM device to 
guide insulin therapy. The STAR CGM protocol gave good 
performance and reduced workload by ~50%. The increase of 
hypoglycaemic events compared to the current STAR protocol 
was of concern but in comparison to other published protocols 
it is still a very low level of hypoglycaemia and is well under 
the clinically acceptable value of 5% below <4.0mmol/L. The 
amount of hypoglycaemic could be reduced by integrating 
trend data and hypoglycaemic alarms in to the STAR protocol 
allowing glucose boluses to be delivered after alarms 
identified as accurate.  
More importantly this study shows great promised for the 
future of CGM and their use in clinic. With the newer 
generation of sensors being specifically designed for the ICU 
environment promising less error and drift. Results from MC 
using half the noise of guardian data suggests that a workload 
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